Immunomodulation

Adenosine monophosphate has an equivalent in the molecule known as AICAR. In clinical studies, it has been found to reduce the risk of cardiac ischemia occurring after a prior heart attack. Due to its antioxidant characteristics, AICAR may aid in reducing the physiologic effects of ageing. The use of AICAR reduce the consequences of diabetes, autoimmune illnesses, and other inflammatory conditions.

It has been shown that the erythropoietin variation known as ARA-290 may reduce the activity of inflammatory pathways by using paracrine signalling and the innate repair receptors. According to research, ARA-290 may help lower HbA1c levels, improve cholesterol, modify peripheral neuropathies and general neuropathic pain, promote wound regeneration, and alleviate general neuropathic pain.
- Cardiovascular disorders
- Diabetic macular edema
- Diabetic neuropathies
- Neuropathic pain
- Small fiber neuropathy
- Rheumatoid arthritis
- Diabetic nephropathies
- Non-alcoholic steatohepatitis
- Inflammatory bowel diseases
- Systemic lupus erythematosus
- Wounds
 
Total Spray: 82 (490 mcg per spray)

FRESHLY PREPARED SOLUTION

It has been shown that the erythropoietin variation known as ARA-290 may reduce the activity of inflammatory pathways by using paracrine signalling and the innate repair receptors. According to research, ARA-290 may help lower HbA1c levels, improve cholesterol, modify peripheral neuropathies and general neuropathic pain, promote wound regeneration, and alleviate general neuropathic pain.
- Cardiovascular disorders
- Diabetic macular edema
- Diabetic neuropathies
- Neuropathic pain
- Small fiber neuropathy
- Rheumatoid arthritis
- Diabetic nephropathies
- Non-alcoholic steatohepatitis
- Inflammatory bowel diseases
- Systemic lupus erythematosus
- Wounds

BPC-157 is a penta-decapeptide comprised of 15 amino acids. It has been demonstrated in experiments conducted on animals to hasten the recovery process of a wide variety of wounds, including those affecting the muscle, tendons, and ligaments. In addition to this, it has been shown that BPC-157 helps prevent gastrointestinal ulcers and protects organs from damage. BPC-57 treats leaky gut, irritable bowel syndrome (IBS), gastrointestinal cramps, and Crohn's disease by exerting a systemic effect on the digestive tract. It has been shown that this particular peptide has analgesic properties. Recent studies have shown that it may hasten the healing process of burns on the skin by enhancing blood flow to the areas that have been injured. BPC-157 is a candidate for use as a therapeutic tool in the treatment of wound healing since it considerably accelerates the synthesis of reticulin and collagen, as well as angiogenesis, and it stimulates the infiltration of macrophages and fibroblasts. BPC-157 has been shown to have effects on:
- Fast recovery from muscle tears
- Wound healing
- Ligament healing
- Healing and prevention of gastric ulcers and inflammatory bowel diseases
- Blood vessel growth
- The coagulation cascade
- Nitric oxide generation
- Immune system function
- Gene expression Hormone regulation

BPC-157 is a penta-decapeptide comprised of 15 amino acids. It has been shown to have effects on:
- Fast recovery from muscle tears
- Wound healing
- Ligament healing
- Healing and prevention of gastric ulcers and inflammatory bowel diseases
- Blood vessel growth
- The coagulation cascade
- Nitric oxide generation
- Immune system function
- Gene expression Hormone regulation

Thymosin Beta-4 is a 43 amino acid peptide sequence. Recent research and clinical trials done utilizing TB-500 (Thymosin Beta 4) have established that it has a variety of advantages, including the following:
- Improves blood vessel growth
- Controls wound healing
- Reduces inflammation
- Minimises oxidative injury to the heart and central nervous system
- Additionally, it aids in tissue regeneration, remodeling, and protection of wounded or damaged tissues.

BPC-157 is a penta-decapeptide comprised of 15 amino acids. It has been demonstrated in experiments conducted on animals to hasten the recovery process of a wide variety of wounds, including those affecting the muscle, tendons, and ligaments. In addition to this, it has been shown that BPC-157 helps prevent gastrointestinal ulcers and protects organs from damage. BPC-57 treats leaky gut, irritable bowel syndrome (IBS), gastrointestinal cramps, and Crohn's disease by exerting a systemic effect on the digestive tract. It has been shown that this particular peptide has analgesic properties. Recent studies have shown that it may hasten the healing process of burns on the skin by enhancing blood flow to the areas that have been injured. BPC-157 is a candidate for use as a therapeutic tool in the treatment of wound healing since it considerably accelerates the synthesis of reticulin and collagen, as well as angiogenesis, and it stimulates the infiltration of macrophages and fibroblasts. BPC-157 has been shown to have effects on:
- Fast recovery from muscle tears
- Wound healing
- Ligament healing
- Healing and prevention of gastric ulcers and inflammatory bowel diseases
- Blood vessel growth
- The coagulation cascade
- Nitric oxide generation
- Immune system function
- Gene expression Hormone regulation
 
Total Spray: 82 (365 mcg per spray)

FRESHLY PREPARED SOLUTION

BPC-157 is a penta-decapeptide comprised of 15 amino acids. It has been shown to have effects on:
- Fast recovery from muscle tears
- Wound healing
- Ligament healing
- Healing and prevention of gastric ulcers and inflammatory bowel diseases
- Blood vessel growth
- The coagulation cascade
- Nitric oxide generation
- Immune system function
- Gene expression Hormone regulation

Thymosin Beta-4 is a 43 amino acid peptide sequence. Recent research and clinical trials done utilizing TB-500 (Thymosin Beta 4) have established that it has a variety of advantages, including the following:
- Improves blood vessel growth
- Controls wound healing
- Reduces inflammation
- Minimises oxidative injury to the heart and central nervous system
Additionally, it aids in tissue regeneration, remodeling, and protection of wounded or damaged tissues.

Total Spray: 82 (BPC-157 365 mcg + TB-500 182 mcg per spray)
FRESHLY PREPARED SOLUTION

Arthritis, Cancer, Pain, Low energy, High blood pressure, High cholesterol, Heart disease, Glaucoma. Depression. Antioxidant, Liver problems, Food allergies, Viral infections, Heavy metal poisoning.

Myo-Inositol Trispyrophosphate Hexasodium Salt (ITPP) is a compound known for enhancing oxygen delivery to tissues by modifying hemoglobin's oxygen affinity. The result is improved metabolic efficiency and better tissue oxygenation. It also exhibits significant antioxidant and anti-inflammatory properties, and various studies have published very promising results in anti-aging, cancer treatment, and the management of degenerative diseases such as Alzheimer's and Parkinson's.

STRUCTURE
Sequence:  γ-Glu-Cys-Gly
Molecular Formula: C10H17N3O6S
Molecular Weight: 307.33 g/mol
PubChem CID: 124886
CAS No: 170-18-8
Peptide purity: Greater than 98%
Other details: No TFA Salt, No Mannitol
Storage: Lyophilized peptide must be stored at -20°C and peptide solution at 4°C. 

L-Glutathione has low oral and excellent subcutaneous bioavailability.

A brief bioregulatory peptide called livagen directly affects the structure and operation of DNA. It is most recognized for its capacity to decondensed chromatin, which enhances the "youthful" profile of cells and increases the expression of certain genes. The immune system's lymphocytes have been the subject of the greatest research. Livagen has been shown to work via these cells to stimulate the immune system and combat diseases of the heart, gastrointestinal tract, immunological system, or central nervous system. In terms of nociception and pain management, livagen research has also been promising. The potential of Livagen will be further unlocked by ongoing study, which will also advance human knowledge of the aging and senescence processes.
 
Total Spray: 82 (1,22 mg per spray)


FRESHLY PREPARED SOLUTION

A brief bioregulatory peptide called livagen directly affects the structure and operation of DNA. It is most recognized for its capacity to decondensed chromatin, which enhances the "youthful" profile of cells and increases the expression of certain genes. The immune system's lymphocytes have been the subject of the greatest research. Livagen has been shown to work via these cells to stimulate the immune system and combat diseases of the heart, gastrointestinal tract, immunological system, or central nervous system. In terms of nociception and pain management, livagen research has also been promising. The potential of Livagen will be further unlocked by ongoing study, which will also advance human knowledge of the aging and senescence processes.